These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8103205)

  • 1. Widespread deficits in somatostatin but not neuropeptide Y concentrations in Alzheimer's disease cerebral cortex.
    Gabriel SM; Bierer LM; Harotunian V; Purohit DP; Perl DP; Davis KL
    Neurosci Lett; 1993 May; 155(1):116-20. PubMed ID: 8103205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin and neuropeptide Y immunoreactivity in Parkinson's disease dementia with Alzheimer's changes.
    Beal MF; Clevens RA; Mazurek MF
    Synapse; 1988; 2(4):463-7. PubMed ID: 2903567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A quantitative assessment of somatostatin-like and neuropeptide Y-like immunostained cells in the frontal and temporal cortex of patients with Alzheimer's disease.
    Davies CA; Morroll DR; Prinja D; Mann DM; Gibbs A
    J Neurol Sci; 1990 Apr; 96(1):59-73. PubMed ID: 1972185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The regional distribution of somatostatin and neuropeptide Y in control and Alzheimer's disease striatum.
    Beal MF; Mazurek MF; McKee MA
    Neurosci Lett; 1987 Aug; 79(1-2):201-6. PubMed ID: 2890123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer's disease.
    Beal MF; Mazurek MF; Chattha GK; Svendsen CN; Bird ED; Martin JB
    Ann Neurol; 1986 Sep; 20(3):282-8. PubMed ID: 3767313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of somatostatin and neuropeptide Y distribution in monkey brain.
    Beal MF; Mazurek MF; Martin JB
    Brain Res; 1987 Mar; 405(2):213-9. PubMed ID: 3567602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease.
    Beal MF; Mazurek MF; Ellison DW; Swartz KJ; McGarvey U; Bird ED; Martin JB
    Ann Neurol; 1988 Jun; 23(6):562-9. PubMed ID: 2900622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Widespread reduction of somatostatin-like immunoreactivity in the cerebral cortex in Alzheimer's disease.
    Beal MF; Mazurek MF; Svendsen CN; Bird ED; Martin JB
    Ann Neurol; 1986 Oct; 20(4):489-95. PubMed ID: 3789664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of regional somatostatin and neuropeptide Y distribution in rat striatum and brain.
    Beal MF; Chattha GK; Martin JB
    Brain Res; 1986 Jul; 377(2):240-5. PubMed ID: 3755369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: normal anatomy and alterations in Alzheimer's disease.
    Kowall NW; Beal MF
    Ann Neurol; 1988 Feb; 23(2):105-14. PubMed ID: 2897822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin and neuropeptide Y are unaltered in the amygdala in schizophrenia.
    Beal MF; Svendsen CN; Bird ED; Martin JB
    Neurochem Pathol; 1987 Jun; 6(3):169-76. PubMed ID: 2888067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential sparing of somatostatin-neuropeptide Y and cholinergic neurons following striatal excitotoxin lesions.
    Beal MF; Kowall NW; Swartz KJ; Ferrante RJ; Martin JB
    Synapse; 1989; 3(1):38-47. PubMed ID: 2563916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex.
    Gabriel SM; Davidson M; Haroutunian V; Powchik P; Bierer LM; Purohit DP; Perl DP; Davis KL
    Biol Psychiatry; 1996 Jan; 39(2):82-91. PubMed ID: 8717605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholecystokinin and somatostatin in Alzheimer's disease postmortem cerebral cortex.
    Mazurek MF; Beal MF
    Neurology; 1991 May; 41(5):716-9. PubMed ID: 1674117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin-28(1-12)-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex.
    Beal MF; Benoit R; Mazurek MF; Bird ED; Martin JB
    Brain Res; 1986 Mar; 368(2):380-3. PubMed ID: 2870772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cysteamine on somatostatin and neuropeptide Y in rat striatum and cortical synaptosomes.
    Chattha GK; Beal MF
    Brain Res; 1987 Jan; 401(2):359-64. PubMed ID: 3815102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased somatostatin immunoreactivity but not neuropeptide Y immunoreactivity in cerebral cortex in senile dementia of Alzheimer type.
    Dawbarn D; Rossor MN; Mountjoy CQ; Roth M; Emson PC
    Neurosci Lett; 1986 Sep; 70(1):154-9. PubMed ID: 2877420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cortical somatostatinergic system not affected in Alzheimer's and Parkinson's diseases.
    Whitford C; Candy J; Edwardson J; Perry R
    J Neurol Sci; 1988 Aug; 86(1):13-8. PubMed ID: 2902199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galanin-like immunoreactivity is increased in the postmortem cerebral cortex from patients with Alzheimer's disease.
    Gabriel SM; Bierer LM; Davidson M; Purohit DP; Perl DP; Harotunian V
    J Neurochem; 1994 Apr; 62(4):1516-23. PubMed ID: 7510783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin immunoreactivity is reduced in Parkinson's disease dementia with Alzheimer's changes.
    Beal MF; Mazurek MF; Martin JB
    Brain Res; 1986 Nov; 397(2):386-8. PubMed ID: 3801878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.